Haloperidol induced Parkinson’s disease mice model and motor-function modulation with Pyridine-3-carboxylic acid

Abstract

Introduction: Motor-function modulation through Pyridine-3-carboxylic acid was assessed against. Haloperidol induced Parkinson’s disease (PD) in albino-mice. The objectives of this study were to test the effect of Haloperidol in development of PD, effectiveness of Pyridine-3-carboxylic acid in mice and evaluation of the motor-function changes in mice before and after treatment. Methods: The study was divided into 3 phases: During Phase-I (randomization), all the subjects were randomly divided into 4 groups and trained for wire-hanging, grip strength, vertical rod and swim tests for 1 week. During Phase-II (disease induction), PD was induced by intra-peritoneal (ip) administration of Haloperidol (HP) in a dose of 1 mg/kg/d for 7 days. Group-A comprised of healthy controls, Group-B (Diseased), Group-C (HP+Pyridine-3-carboxylic acid 7.15 mg/kg/d) and Group-D (HP+Pyridine-3-carboxylic acid15 mg/kg/d). Results: Pyridine-3-carboxylic acid treatment continued for 5 weeks. During Phase-III the above mention tests were performed and the effects of Pyridine-3-carboxylic acid were recorded. However, in swim test Group D is statistically insignificant as compared to Group B (p=0.284). In recent study, haloperidol is found to be effective in inducing motor function anomalies likewise in Parkinson’s disease including movement slowness, difficulties with gait and balance. Conclusion: oral administration of Pyridine-3-carboxylic acid improved Motor-function changes in diseased mice. Therefore, it is concluded that Pyridine-3-carboxylic acid may help to alleviate PD symptoms.